Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of veonetinib (AL8326) in previously treated SCLC, NSCLC, and RCC
2023-509067-24-01Phase 2Authorised
- Sponsor
- Advenchen Laboratories
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of AL8326 in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) (3 cohorts), sponsored by Advenchen Laboratories. Primary endpoints: Optimal biological dose and Objective response rate. Planned start Jun 2025; status: authorised.
02
Drugs
AL8326
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2023-509067-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509067-24-01.